Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kadarnath Boodram

Internal Medicine Petersburg, VA Medical Doctor

NPI 1679546923 CMS profile 30862

801 S Adams St, Petersburg, VA 23803

Open in the dashboard

General payments

$9,017

515 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kadarnath Boodram of Petersburg, VA is reported in the CMS Open Payments database as having received $9,017 across 515 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,091 59
2024 General $1,217 60
2023 General $1,250 63
2022 General $893 52
2021 General $1,443 84
2020 General $1,817 115
2019 General $1,305 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kadarnath Boodram
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kadarnath Boodram were reported at $1,091. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kadarnath Boodram Internal Medicine median Middle half National median
2019 $1,305 $159 $48–$570 $163
2020 $1,817 $119 $33–$402 $114
2021 $1,443 $135 $37–$521 $132
2022 $893 $141 $42–$496 $149
2023 $1,250 $149 $45–$519 $160
2024 $1,217 $154 $47–$537 $164
2025 $1,091 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $1,082 67 payments
  2. Novo Nordisk Inc $871 53 payments
  3. AstraZeneca Pharmaceuticals LP $827 50 payments
  4. GlaxoSmithKline, LLC. $790 37 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $691 36 payments
  6. Pfizer Inc. $672 40 payments
  7. Sanofi-Aventis U.S. LLC $614 35 payments
  8. Amgen Inc. $557 27 payments
  9. Amarin Pharma Inc. $541 33 payments
  10. AbbVie, Inc. $463 26 payments
  11. Other $1,907 111 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,929 508 payments
  2. Education $87 7 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $790 37 payments
  2. Kerendia $691 36 payments
  3. TRULICITY $682 43 payments
  4. Ozempic $634 37 payments
  5. RYBELSUS $558 31 payments
  6. Vascepa $469 29 payments
  7. FARXIGA $441 27 payments
  8. MOUNJARO $427 22 payments
  9. COLOGUARD $398 25 payments
  10. JARDIANCE $370 26 payments
  11. Other $7,408 423 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 138 drugs

Part D claims

9,732

Median for Internal Medicine: 777

Drug cost

$890,430

Median for Internal Medicine: $73,373

Branded share of claims

20.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 120 $126,144
Ozempic Semaglutide Brand 82 $125,608
Eliquis Apixaban Brand 58 $70,782
Mounjaro Tirzepatide Brand 41 $67,286
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 79 $61,238
Farxiga Dapagliflozin Propanediol Brand 66 $61,206
Januvia Sitagliptin Phosphate Brand 62 $56,018
Trulicity Dulaglutide Brand 35 $35,001
Linzess Linaclotide Brand 24 $24,051
Xarelto Rivaroxaban Brand 14 $22,746

The 10 drugs with the highest cost, of 138 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$225,913

Of which drugs: $48,644

Medicare patients

367

Average age 76

Services billed

4,564

232 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 44%
Chronic kidney disease 41%
Arthritis 38%
Ischemic heart disease 22%
Depression 19%
COPD 18%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 65 65 $18,647
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 114 114 $17,992
Vaccine for influenza for injection into muscle 90653 Office 142 142 $11,618

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $245
$245 — —
MOUNJARO
  • Lilly USA, LLC $96
$96 41 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $89
$89 79 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $52
  • Lilly USA, LLC $23
$75 120 —
RYBELSUS
  • Novo Nordisk Inc $59
$59 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

515 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record